First patient randomised as study advances novel pan phosphate transporter inhibitor
News
Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
Move sharpens Mission’s focus on CNS pipeline as renal specialist takes AKI asset forward
Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
Long‑term follow‑up reinforces momentum toward registration‑enabling trial
ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
Company to showcase INSTI-powered innovation across treatment and PrEP
Jasper Therapeutics merges with Kira Pharmaceuticals
Combined company to advance biologics for immunologically‑driven disorders
EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy
Partnership to support first‑in‑human trial of EPY201 in epilepsy
NICE backs finerenone for heart failure
Guidance expands treatment options for patients
EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC
Breakwater data show significant survival gains over standard chemotherapy
FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer’s disease
At‑home autoinjector option offers new flexibility for patients and care partners
SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms
Non-hormonal option to be made available for patients unsuitable for HRT
SMC backs Columvi combination for second-line lymphoma treatment in Scotland
Roche therapy accepted for adults ineligible for stem cell transplant
Pluripotent stem cell trial for Huntington’s disease
Early-stage study marks milestone for regenerative medicine
Jascayd gains UK licence for treatment of pulmonary fibrosis
New option for adults with IPF and PPF
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
Compass Pathways reports six‑month data confirming durable profile of COMP360
Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission
